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years ago, first clinical trials on safety and immunogenicity. In
the meantime more than 25,000 women have been included into
several efficacy trials which demonstrated protection against
persistent infection with HPV 16 and 18 and against the develop-
ment of precursor lesions to cervical cancer. Although the ulti-
mate proof of success, i.e. reduction of cancer incidence still
requires the immunization of large populations and many years
of follow-up, the existing data are so persuasive that the first
marketing of the vaccine is expected to be announced in mid
2006. Yet several questions such as the duration of protection,
the need development of for post-exposure vaccination strate-
gies and availability of such vaccine in low-budget countries
are open and will be discussed.
doi:10.1016/j.ejcsup.2006.04.039
S39. IDENTIFICATION OF POTENTIAL TARGET ANTIGENS FOR
IMMUNOTHERAPY APPROACHES
Dirk Ja¨ger. Medizinische Onkologie, Nationales Centrum fu¨r
Tumorerkrankungen, Universita¨tsklinik Heidelberg, Germany.
Immunotherapy approaches in cancer rely on the identification of
suitable antigens that can be used as targets for therapeutic
approaches. The ideal target antigen is highly and homogenously
expressed in cancer, but not or low level expressed in normal tis-
sues. Using different cloning techniques, several potential target
antigens have been identified, some of these antigens are already
being evaluated in clinical trials. We followed a cloning strategy
called SEREX that identifies tumor antigens based on a spontane-
ous humoral immune response in patients. Using this technique
we identified 2 new tumor associated antigens that belong to the
group of differentiation antigens: NY-BR-1 as a new breast differ-
entiation antigen and RAB38/NY-MEL-1 as a new melanocyte dif-
ferentiation antigen.
NY-BR-1 is not expressed in normal tissues except in nor-
mal mammary gland and testis, but it is highly expressed in
70% of breast cancers. Antigen positive cancers maintain the
expression in metastatic lesions. Spontaneous antibody
responses occur in about 10% of breast cancer patients. We
identified 2 HLA-A2 restricted NY-BR-1 derived epitopes that
were recognized by CD8+ T cells from patients with NY-BR-1
expressing cancers. Both epitopes are naturally processed and
presented.
RAB38/NY-MEL-1 is expressed in melanocytes and at low level
in adrenal gland, all other normal tissues are RAB38/NY-MEL-1
mRNA negative. Spontaneous humoral immune responses are
frequent in melanoma patients but not in normal individuals,
in patients with vitiligo or with cancers other than melanoma.
We recently identified a HLA-A2 restricted RAB38/NY-MEL-1
derived epitope that is naturally processed and presented and
recognized by CD8 T cells.
Both new antigens, NY-BR-1 and RAB38/NY-MEL-1 are being
evaluated as targets for T cell based immunotherapy strategies
in Phase-I trials.
doi:10.1016/j.ejcsup.2006.04.040
S40. T CELL BASED IMMUNOTHERAPY – CHANGES AND
CHALLENGES
Volker Schirrmacher. Division of Cellular Immunology, German
Cancer Research Center, Heidelberg, Germany.
Advances in cellular and molecular immunology have led to the
development of strategies for effective augmentation of anti-
tumor immune-responses in cancer patients. This presentation
focuses on the manipulation of T cell immunity either by
active-specific immunization with tumor vaccines1–4 or by adop-
tive immunotherapy with immune T cells.5,6 Such therapies offer
exquisite specificity of tumor recognition based on the ability of
the T cell to distinguish single amino acid differences in any pro-
tein from any compartment of the tumor cell.
Recent analyses of bone marrow samples from patients with
a variety of different cancers revealed the existence of cancer
reactive memory T cells in a high proportion and at high fre-
quencies.5–9 A fine specificity analysis revealed individuality (i)
of response patterns to multiple tumor associated antigens
(TAAs), (ii) of the size and (iii) of the specificity of the memory
repertoire in the bone marrow of cancer patients. These findings
challenge immunotherapy approaches targeting single TAAs.
Future strategies will be discussed for the exploitation of the
TAA memory repertoire of cancer patients. In ‘‘proof of princi-
ple’’ studies it was demonstrated to have great therapeutic
potential.5,6
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S41. TARGETING THE APOPTOTIC PATHWAY TO INDUCE
RADIORESISTANCE IN NORMAL TISSUE AND STEM CELLS
Frederik Wenz. Department of Radiation Oncology, Mannheim
Medical Center, University of Heidelberg, Germany.
Novel strategies in clinical radiotherapy have the goal to
increase the therapeutic index i.e. effective tumor cell kill while
sparing the normal tissue. This can be achieved by either phys-
ical selectivity when the tumor is well circumscribed or by bio-
logical selectivity when normal tissue is present in the
treatment volume. Biological selectivity can be achieved by tar-
geting tissue properties which are only present either in tumor
or normal tissue cells.
Radiation induced apoptosis is a rare event as compared to
mitogenic death in epithelial tumor cells. In contrast, radiation
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